CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DSTAG3UnderexpressionPredictiveSupportsResistanceMelanomaVemurafenibShen et al., 2016
CMAP2K1Q56_V60delPredictiveSupportsSensitivity/ResponseOvarian Serous CarcinomaSelumetinibGrisham et al., 2015
DBRAFL505HPredictiveSupportsResistanceMelanomaVemurafenibWagenaar et al., 2014
BERBB2AmplificationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
BERBB2AmplificationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseColorectal CancerLapatinib,TrastuzumabSartore-Bianchi et al., 2016
BSTAG2MUTATIONPrognosticSupportsPoor OutcomeEwing Sarcoma Of BoneCrompton et al., 2014
BKRASMutationPrognosticSupportsPoor OutcomeLung AdenocarcinomaJohnson et al., 2013
BEGFRMutationPrognosticSupportsBetter OutcomeLung AdenocarcinomaJohnson et al., 2013
DSOX10LossPredictiveSupportsResistanceMelanomaVemurafenibSun et al., 2014
DFGF2EXPRESSIONPredictiveSupportsResistanceAcute Myeloid LeukemiaQuizartinibTraer et al., 2016
CEIF1AXMUTATIONPrognosticSupportsBetter OutcomeUveal MelanomaMartin et al., 2013
APAX8ExpressionDiagnosticSupportsPositiveFemale Reproductive Organ CancerHeidarpour et al., 2014
BKITD816VPredictiveSupportsSensitivity/ResponseSystemic MastocytosisMidostaurinGotlib et al., 2016
BKITD816VPrognosticSupportsPoor OutcomeSystemic MastocytosisJawhar et al., 2016
BEGFRMutationPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinibPark et al., 2016
DSGK1OverexpressionPredictiveSupportsSensitivity/ResponseBreast CancerSGK1-Inh,AlpelisibCastel et al., 2016
DCCNE1AmplificationPredictiveSupportsSensitivity/ResponseOvarian Serous CystadenocarcinomaAkt Inhibitor MK2206,DinaciclibAu-Yeung et al., 2017
BPTENDeletionPrognosticSupportsPoor OutcomeProstate CancerGao et al., 2016
DNF2LossPredictiveSupportsSensitivity/ResponseThyroid Gland CarcinomaSelumetinibGarcia-Rendueles et al., 2015
BBRAFV600EPredictiveSupportsSensitivity/ResponseMelanomaVemurafenibFlaherty et al., 2010
BEWSR1::FLI1FusionDiagnosticSupportsPositiveEwing Sarcoma Of BoneTurc-Carel et al., 1988
BMTHFRA222VPredisposingSupportsProtectivenessPancreatic CancerWu et al., 2016
BMTHFRA222VPredictiveSupportsSensitivity/ResponseRectum CancerFluorouracilNikas et al., 2015
BHOXB13G84EPredisposingSupportsPredispositionProstate CancerBeebe-Dimmer et al., 2015
BERBB2AmplificationPredictiveSupportsSensitivity/ResponseHer2-receptor Positive Breast CancerTrastuzumab EmtansineBurris et al., 2011
BSTK11MutationPredisposingSupportsPredispositionPeutz-Jeghers SyndromeJelsig et al., 2016
BBTKC481SPredictiveSupportsResistanceChronic Lymphocytic LeukemiaIbrutinibMaddocks et al., 2015
Cv::ALKFusionDiagnosticSupportsPositiveInflammatory Myofibroblastic TumorGriffin et al., 1999
BCYP2D6Loss-of-functionPrognosticDoes Not SupportPoor OutcomeBreast CancerLum et al., 2013
BUGT1A1UGT1A1*60PredictiveSupportsAdverse ResponseCancerBelinostatGoey et al., 2016
BWWTR1::CAMTA1FusionDiagnosticSupportsPositiveMalignant Epithelioid HemangioendotheliomaErrani et al., 2011
BHOXB13G84EPredisposingSupportsPredispositionProstate CancerZhang et al., 2016
BFGFR2::BICC1FusionDiagnosticSupportsPositiveCholangiocarcinomaArai et al., 2014
BFGFR2::AHCYL1FusionDiagnosticSupportsPositiveCholangiocarcinomaArai et al., 2014
BCDKN2BMETHYLATIONPrognosticSupportsPoor OutcomeAcute Promyelocytic LeukemiaChim et al., 2006
CPTPRDV253IPredictiveSupportsSensitivity/ResponseEwing Sarcoma Of BoneTeprotumumab,CixutumumabJiang et al., 2013
BEGFRT790MPredictiveSupportsResistanceLung Non-small Cell CarcinomaAfatinibSun et al., 2013
CMETD1228VPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCabozantinibBahcall et al., 2016
CMETD1228VPredictiveSupportsResistanceLung Non-small Cell CarcinomaSavolitinibBahcall et al., 2016
CRUNX1K83EPredisposingSupportsPredispositionAcute Myeloid LeukemiaMichaud et al., 2002
CRUNX1R135FSX177PredisposingSupportsPredispositionAcute Myeloid LeukemiaMichaud et al., 2002
CETV6::NTRK3Fusion AND NTRK3 G623RPredictiveSupportsResistanceMammary Analogue Secretory CarcinomaEntrectinibDrilon et al., 2016
CVHLA149S (c.445G>T)PredisposingSupportsPredispositionVon Hippel-Lindau DiseaseAtuk et al., 1998
DJAK1S703IPredictiveSupportsSensitivity/ResponseHepatocellular CarcinomaRuxolitinibYang et al., 2016
BEPCAM3' Exon DeletionPredisposingSupportsPredispositionLynch SyndromeKuiper et al., 2011
BBRAFV600EPredictiveSupportsSensitivity/ResponseColorectal CancerVemurafenib,Irinotecan,CetuximabHong et al., 2016
DAKT3OverexpressionPredictiveSupportsResistanceBreast CancerAkt Inhibitor MK2206Stottrup et al., 2016
EAKT3OverexpressionPredictiveSupportsSensitivity/ResponseTriple-receptor Negative Breast CancerPan-AKT Kinase Inhibitor GSK690693Chin et al., 2014
DBRCA1Loss-of-functionPredictiveSupportsSensitivity/ResponseBreast CancerQuarfloxin,PidnarulexXu et al., 2017
Page 13 of 96
PreviousNext